Literature DB >> 6202344

Monoclonal antibodies detecting antigenic determinants with restricted expression on erythroid cells: from the erythroid committed progenitor level to the mature erythroblast.

T Yokochi, M Brice, P S Rabinovitch, T Papayannopoulou, G Stamatoyannopoulos.   

Abstract

Two new cell surface antigens specific for the erythroid lineage were defined with cytotoxic IgM monoclonal antibodies (McAb) (EP-1; EP-2) that were produced using BFU-E-derived colonies as immunogens. These two antigens are expressed on in vivo and in vitro derived adult and fetal erythroblasts, but not on erythrocytes. They are not detectable on resting lymphocytes, concanavalin-A (Con-A) activated lymphoblasts, granulocytes, and monocytes or granulocytic cells or macrophages present in peripheral blood or harvested from CFU-GM cultures. Cell line and tissue distributions distinguish McAb EP-1 and EP-2 from all previously described monoclonal antibodies. McAb EP-1 (for erythropoietic antigen-1) inhibits the formation of BFU-E and CFU-E, but not CFU-GM, colonies in complement-dependent cytotoxicity assays. By cell sorting analysis, about 90% of erythroid progenitors (CFU-E, BFU-E) were recovered in the antigen-positive fraction. Seven percent of the cells in this fraction were progenitors (versus 0.1% in the negative fraction). The expression of EP-1 antigen is greatly enhanced in K562 cells, using inducers of hemoglobin synthesis. McAb EP-2 fails to inhibit BFU-E and CFU-E colony formation in complement-dependent cytotoxicity assays. EP-2 antigen is predominantly expressed on in vitro derived immature erythroblasts, and it is weakly expressed on mature erythroblasts. The findings with McAb EP-1 provide evidence that erythroid progenitors (BFU-E and CFU-E) express determinants that fail to be expressed on other progenitor cells and hence appear to be unique to the erythroid lineage. McAb EP-1 and EP-2 are potentially useful for studies of erythroid differentiation and progenitor cell isolation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6202344

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow.

Authors:  S Koizumi; G A Curt; R L Fine; J D Griffin; B A Chabner
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

2.  Definitive-like erythroid cells derived from human embryonic stem cells coexpress high levels of embryonic and fetal globins with little or no adult globin.

Authors:  Kai-Hsin Chang; Angelique M Nelson; Hua Cao; Linlin Wang; Betty Nakamoto; Carol B Ware; Thalia Papayannopoulou
Journal:  Blood       Date:  2006-04-27       Impact factor: 22.113

3.  Effect of methotrexate on intracellular folate pools in purified myeloid precursor cells from normal human bone marrow.

Authors:  J Baram; C J Allegra; R L Fine; B A Chabner
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

4.  Mechanism of Hb F stimulation by S-stage compounds. In vitro studies with bone marrow cells exposed to 5-azacytidine, Ara-C, or hydroxyurea.

Authors:  R Galanello; G Stamatoyannopoulos; T Papayannopoulou
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

5.  Propagation of human parvovirus B19 in primary culture of erythroid lineage cells derived from fetal liver.

Authors:  N Yaegashi; H Shiraishi; T Takeshita; M Nakamura; A Yajima; K Sugamura
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

6.  Differentiation potential of o bombay human-induced pluripotent stem cells and human embryonic stem cells into fetal erythroid-like cells.

Authors:  Fatemeh Ganji; Saeid Abroun; Hossein Baharvand; Nasser Aghdami; Marzieh Ebrahimi
Journal:  Cell J       Date:  2015-01-13       Impact factor: 2.479

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.